PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32830517-3	2021	OBJECTIVE: To describe the use of fixed-dose phenobarbital monotherapy for the management of patients at risk for AWS in the surgical-trauma intensive care unit.	Phenobarbital	45-58	jagged canonical Notch ligand 1	Homo sapiens	114-117	
32830517-4	2021	METHODS: Surgical-trauma critically ill patients who received phenobarbital monotherapy, loading dose followed by a taper regimen, for the management of AWS were included in this evaluation.	Phenobarbital	62-75	jagged canonical Notch ligand 1	Homo sapiens	153-156	
32830517-5	2021	The effectiveness of phenobarbital monotherapy to treat AWS and prevent development of AWS-related complications were evaluated.	Phenobarbital	21-34	jagged canonical Notch ligand 1	Homo sapiens	56-59	
32830517-7	2021	RESULTS: A total of 31 patients received phenobarbital monotherapy; the majority of patients were at moderate risk for developing AWS (n = 20; 65%) versus high risk (n = 11; 35%).	Phenobarbital	41-54	jagged canonical Notch ligand 1	Homo sapiens	130-133	
32830517-12	2021	CONCLUSION AND RELEVANCE: Fixed-dose phenobarbital monotherapy appears to be well tolerated and effective in the management of AWS.	Phenobarbital	37-50	jagged canonical Notch ligand 1	Homo sapiens	127-130	
32830517-13	2021	Further evaluation is needed to determine the extent of benefit with the use of phenobarbital monotherapy for management of AWS.	Phenobarbital	80-93	jagged canonical Notch ligand 1	Homo sapiens	124-127